New drug combo tested for spreading prostate cancer
NCT ID NCT06689163
Summary
This study is testing a new oral drug, HRS-1167, given alongside two standard prostate cancer medications (abiraterone and prednisone) in men whose cancer has spread. The main goals are to find a safe and effective dose and to see how well the combination works to control the cancer. Researchers will monitor side effects closely and track how the cancer responds to treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital Of Anhui Medical University
RECRUITINGHefei, Anhui, 230000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.